

Applicants : Robert L. Fine et al.  
U.S. Serial No.: 10/587,606  
Filed : November 13, 2006  
Page : 2 of 18 of Amendment and SIDS

**Amendments to the Claims:**

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A polypeptide comprising a ~~first segment of continuous amino acids, a segment of which has~~ having the sequence ~~AQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD (SEQ ID NO. 1)~~ covalently linked to a second segment of continuous amino acids having the sequence ~~DSDPGETKFMLKKHRSTSQCKKSKLHSSHARSGGPEKGAQA (SEQ ID NO. 2)~~ AQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGETKFMLKKHRSTSQCKKSKLHSSHARSGGPEKGAQA (SEQ ID NO. 3), wherein the glycine may be present or absent.
2. (Cancelled)
3. (Original) The polypeptide of claim 1, further comprising a six repeat histidine tag attached to the N-terminus of the polypeptide.
4. (Original) The polypeptide of claim 1, further comprising a membrane carrier peptide attached to the C-terminus of the polypeptide.
5. (Original) The polypeptide of claim 4, wherein the membrane carrier peptide (Ant) comprises amino acids having the sequence KKWKMRNQNFWVKVQRG (SEQ ID NO. 8).
6. (Original) The polypeptide of claim 1, further comprising:

Applicants : Robert L. Fine et al.  
U.S. Serial No.: 10/587,606  
Filed : November 13, 2006  
Page : 3 of 18 of Amendment and SIDS

- a. a six repeat histidine tag attached to the N-terminus of the polypeptide; and
- b. a membrane carrier peptide attached to the C-terminus of the polypeptide.

7. (Cancelled).

8. (Cancelled).

9. (Currently Amended) The polypeptide of claim 1 7, comprising consecutive amino acids having the ~~palindromic~~ sequence

AQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGETKF  
MLKKHRSTSQGKKSKLHSSHARSGGPEKGAQA[glycine]AQAGKEPGGSRAHSSHLK  
SKKGQSTSRHKKLMFKTEGPDSD[glycine]DSDPGETKFMLKKHRSTSQGKKSKLHS  
SHARSGGPEKGAQA (SEQ ID NO. 5), wherein ~~the~~ each glycine may  
be present or absent.

10. (Original) The polypeptide of claim 9, further comprising a six repeat histidine tag attached to the N-terminus of the polypeptide.

11. (Original) The polypeptide of claim 9, further comprising a membrane carrier peptide attached to the C-terminus of the polypeptide.

12. (Original) The polypeptide of claim 11, wherein the membrane carrier peptide comprises amino acids having the sequence KKWKMRNRFVVKVQRG (SEQ ID NO. 8).

13. (Original) The polypeptide of claim 9, further comprising:

- a. a six repeat histidine tag attached to the N-terminus of the polypeptide; and

Applicants : Robert L. Fine et al.  
U.S. Serial No.: 10/587,606  
Filed : November 13, 2006  
Page : 4 of 18 of Amendment and SIDS

b. a membrane carrier peptide attached to the C-terminus of the polypeptide.

14. (Currently Amended) The polypeptide of claim 1 8, comprising consecutive amino acids having the ~~palindromic~~ sequence  
DSDPGETKFMLKKHRSTSQGKSKLHSSHARSGGPEKGAQA[glycine]AQAGKEPGG  
SRAHSSHLKSKKGQSTSRHKLMFKTEGPDSD[glycine]DSDPGETKFMLKKHRSTS  
QGKSKLHSSHARSGGPEKGAQA[glycine]AQAGKEPGGSRAHSSHLKSKKGQSTSR  
HKLMFKTEGPDSD (SEQ ID NO. 6), wherein ~~the~~ each glycine may be present or absent.
15. (Original) The polypeptide of claim 14, further comprising a six repeat histidine tag attached to the N-terminus of the polypeptide.
16. (Original) The polypeptide of claim 14, further comprising a membrane carrier peptide attached to the C-terminus of the polypeptide.
17. (Original) The polypeptide of claim 16, wherein the membrane carrier peptide comprises amino acids having the sequence KKWKMRNRNQFWVKVQRG (SEQ ID NO. 8).
18. (Original) The polypeptide of claim 14, further comprising:  
a. a six repeat histidine tag attached to the N-terminus of the polypeptide; and  
b. a membrane carrier peptide attached to the C-terminus of the polypeptide.

19-30. (Cancelled)

31. (Previously Presented) A method of treating a subject

Applicants : Robert L. Fine et al.  
U.S. Serial No.: 10/587,606  
Filed : November 13, 2006  
Page : 5 of 18 of Amendment and SIDS

suffering from cancer by administering to the subject the polypeptide of claim 1.

32-35. (Cancelled)

36. (Previously Presented) A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier for treating cancer.

37-40. (Cancelled)

41. (New) A method of treating a subject suffering from cancer by administering to the subject the polypeptide of claim 9.

42. (New) A method of treating a subject suffering from cancer by administering to the subject the polypeptide of claim 14.